Peregrine Capital Management LLC Sells 66,329 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peregrine Capital Management LLC lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 24.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 201,781 shares of the medical equipment provider's stock after selling 66,329 shares during the quarter. Peregrine Capital Management LLC owned about 0.29% of Lantheus worth $12,510,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in LNTH. FMR LLC increased its stake in shares of Lantheus by 198.2% during the third quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider's stock valued at $149,110,000 after acquiring an additional 1,426,465 shares during the period. Vanguard Group Inc. grew its position in Lantheus by 32.9% in the first quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider's stock worth $317,595,000 after buying an additional 1,422,269 shares during the last quarter. Norges Bank acquired a new position in Lantheus in the fourth quarter worth approximately $45,379,000. Point72 Asset Management L.P. acquired a new position in Lantheus in the fourth quarter worth approximately $28,042,000. Finally, Alliancebernstein L.P. grew its position in Lantheus by 18.1% in the fourth quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider's stock worth $162,731,000 after buying an additional 489,203 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on LNTH. TheStreet lowered shares of Lantheus from a "b-" rating to a "c" rating in a research report on Monday, December 18th. Truist Financial reaffirmed a "buy" rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Saturday, January 13th. B. Riley decreased their price objective on shares of Lantheus from $113.00 to $95.00 and set a "buy" rating for the company in a research note on Wednesday, January 10th. Finally, William Blair lowered shares of Lantheus from an "outperform" rating to a "market perform" rating in a research note on Monday, December 18th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $104.14.

Insider Buying and Selling

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company's stock in a transaction dated Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company's stock in a transaction dated Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the business's stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold 94,545 shares of company stock worth $6,168,153 in the last quarter. 2.10% of the stock is currently owned by company insiders.

Lantheus Stock Up 1.1 %

Shares of NASDAQ:LNTH traded up $0.68 during trading on Tuesday, reaching $60.42. 790,020 shares of the company traded hands, compared to its average volume of 1,099,962. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $100.85. The firm has a fifty day simple moving average of $59.66 and a 200 day simple moving average of $63.22. The firm has a market cap of $4.14 billion, a P/E ratio of 13.02 and a beta of 0.54.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The business had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Analysts anticipate that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.